anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multiple myeloma is an incurable blood cancer of plasma cells that occurs in older individuals with a median age at diagnosis of 69 years and a median overall survival of 6-7 years \[Kumar S.K., et al. Leukemia, 2014; Rollig C., et al. Lancet., 2015\]. Over the past years novel agents have been introduced into clinical practice, showing improved overall response rates, progression-free survival and overall survival in patients with multiple myeloma. The main classes of novel agents include proteasome inhibitors, immunomodulatory agents and monoclonal antibodies. These agents are typically used in doublet or triplet regimens that include a chemotherapeutic drug and/or corticosteroid.

Streptococcus pneumoniae (pneumococcus) is a cause of worldwide morbidity and mortality. Patients with multiple myeloma are at high risk of developing life-threatening Streptococcus pneumoniae infections due to chemotherapy-associated immunosuppression. Vaccination is an important preventive strategy against infections caused by S. pneumoniae. In the past, the 23-valent pneumococcal polysaccharide vaccine was recommended. However, polysaccharide vaccines have limited efficacy in cancer and hematology patients, because of the decreased T- and B-cell responses. Clinical efficacy and safety of conjugate pneumococcal vaccines in multiple myeloma patients receiving novel agents have not been studied before.

In this study the investigators wish to study the effect of vaccination with 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel agents (proteasome inhibitors and immunomodulatory drugs). The main aim of this study is to assess the clinical efficacy and safety of 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel agents.
The invention relates to new anti-inflammatory medicine with a bone protection function and composed of glucocorticoid and salvia extract. The new medicine has a better curative effect than existing anti-inflammatory action obtained by singly using the glucocorticoid, is free from damage to bones by the glucocorticoid and is new medicine with the bone protection function. The new anti-inflammatory medicine is composed of prednisone acetate and tanshinol, the optimal ratio of the formula is 1:4, and namely the new anti-inflammatory medicine contains 5 mg of prednisone acetate and 20 mg of tanshinol. The new anti-inflammatory medicine comprises the optimal combination of the prednisone acetate, the tanshinol, salvianolic acid B and protocatechualdehyde. The selected salvia extract includes known components with definite chemical structures and stable ingredients and easy to extract, and the compound prescription can be registered as a chemical drug and be approved to produce. The new anti-inflammatory medicine can replace various kinds of glucocorticoid medicine used clinically in China currently.
BACKGROUND: In patients undergoing total joint arthroplasty, the use of dexamethasone (DEX) may cause perioperative blood glucose (BG) disorders, leading to complications even in patients who do not have diabetes. We aimed to evaluate the effects of different DEX doses on perioperative BG levels.
METHODS: A total of 135 patients who do not have diabetes were randomized into three groups: preoperative intravenous (IV) injection of normal saline (Group A, the placebo group), preoperative IV injection of 10 mg DEX (Group B), and preoperative IV injection of 20 mg DEX (Group C). Postoperative fasting BG (FBG) levels were designated as the primary outcome, while postoperative postprandial BG (PBG) levels were assigned as the secondary outcome. The incidence of complications was recorded. We also investigated the risk factors for FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL.
RESULTS: The FBG levels were higher in Groups B and C than in Group A on postoperative days (PODs) 0 and 1. The PBG levels were lower for Groups A and B compared to Group C on POD 1. No differences in FBG or PBG were detected beyond POD 1. Elevated preoperative glycosylated hemoglobin A1c levels increased the risk of FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL, respectively. However, preoperative IV injection of DEX was not associated with FBG ≥ 140 mg/dL or PBG ≥ 180 mg/dL. No differences were found in postoperative complications among the three groups.
CONCLUSIONS: The preoperative IV administration of 10 or 20 mg DEX in patients who do not have diabetes showed transient effects on postoperative BG after total joint arthroplasty. The preoperative glycosylated hemoglobin A1c level threshold (regardless of the administration or dosage of DEX) that increased the risk for the occurrence of FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL was 5.75 and 5.85%, respectively.
PURPOSE: A pharmaceutical composition containing lactic acid bacteria-derived p14 protein or a gene encoding the protein is provided to minimize side effect and to ensure excellent anticancer effect. CONSTITUTION: A pharmaceutical composition for anticancer contains p14 protein with an amino acid sequence of sequence number 1 or 3 as an active ingredient. The protein is derived from Lactobacillus casei, Lactobacillus paracasei, or Lactobacillus rhamnosus. The molecular weight of the protein is about 14kDa. The composition further contains a pharmaceutically acceptable excipient, diluents, carrier, or buffer. The composition also contains a nucleic acid encoding the protein as an active ingredient. The nucleic acid contains a base of sequence number 2 or 4.
Ursodiol is a bile acid available as 300 mg capsules suitable for oral administration.

Ursodiol (ursodeoxycholic acid), a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain other mammals. It is a bitter-tasting, white or almost white crystalline powder freely soluble in alcohol; slightly soluble in acetone and in methylene chloride; very slightly soluble in water. The chemical name for ursodiol is 3α,7β-Dihydroxy-5β-cholan-24-oic acid (C24H40O4). Ursodiol, USP has a molecular weight of 392.57. Its structure is shown below:

Inactive Ingredients: Corn starch, colloidal silicon dioxide, magnesium stearate, talc, iron oxide red, titanium dioxide, gelatin. The imprinting ink contains shellac, black iron oxide and traces of potassium hydroxide.
Fifty adults( male or female-nonpregnant) whose weight is between 55-85 kg and are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass for CABG or primary valve repair or replacement will be eligible. Patients with any history of abnormal bleeding disorders, urgent or emergent need for surgery, and combination surgeries will be excluded. Blood volume analysis will be performed with the DAXOR Blood Volume Analyzer BVA-100 System and the Volumex HSA I-131 radiopharmaceutical for use for determining circulating volume. Multiple timed sample points will be obtained. The DAXOR blood volume analyzer will batch samples and with input of patients height, weight, gender, time of draw, and corresponding Hct, calculate circulating total blood volume. We hypothesize that Total red cell mass is relatively well conserved( \<20% decrease) during and immediately after surgery as long as major bleeding does not occur. We hypothesize that decrease in Hct during surgery are related to changes in circulating plasma volume. Total red cell O2 carrying capacity and O2 economics will be measured and it is also hypothesized that lowered Hct values, even as low as 15%, do not independently signal a tissue or whole body O2 deficit.
Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established. Consider monitoring for hyperglycemia, new onset diabetes mellitus, or an exacerbation of diabetes mellitus in patients treated with ritonavir.
Symptoms associated with discontinuation of venlafaxine hydrochloride extended-release capsules, other SNRI’s, and SSRI’s have been reported [see Warnings and Precautions (5.5)]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. In clinical trials with venlafaxine hydrochloride extended-release capsules, tapering was achieved by reducing the daily dose by 75 mg at 1 week intervals. Individualization of tapering may be necessary.
Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
Nab-paclitaxel 125 mg/m\^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m\^2 on days D1, D8, D15 of a 28-day cycle.
Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were \> 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
During Phase 1, up to 2 dose levels of TTI-101 with SBRT will be tested using a 3 + 3 dose-escalation design to determine the RP2D. Up to 3 participants may be enrolled with either 0/3 or 1/3 DLT in order to more fully evaluate the safety and tolerability at a given dose level. Therefore, a minimum of 9 patients (3 at dose 0, and 6 at dose 1) and maximum 18 (6 patients at each dose level) will be enrolled in the phase 1.
Excess body weight, suboptimal diet, physical inactivity, alcohol consumption, sleep disruption, and elevated stress are modifiable risk factors associated with the development of chronic diseases. Digital behavioural interventions targeting these factors have shown promise in improving health and reducing chronic disease risk. The Digital Intervention for behaviouR changE and Chronic disease prevenTION (DIRECTION) study is a parallel group, two-arm, randomized controlled trial evaluating the effects of adding healthcare professional guidance and peer support via group-based sessions to a web-based wellness platform (experimental group, n = 90) compared to a self-guided use of the platform (active control group, n = 90) among individuals with a body mass index (BMI) of 30 to <35 kg/m2 and aged 40-65 years. Obesity is defined by a high BMI. The web-based wellness platform employed in this study is My Viva Plan (MVP)®, which holistically integrates nutrition, physical activity, and mindfulness programs. Over 16 weeks, the experimental group uses the web-based wellness platform daily and engages in weekly online support group sessions. The active control group exclusively uses the web-based wellness platform daily. Assessments are conducted at baseline and weeks 8 and 16. The primary outcome is between-group difference in weight loss (kg) at week 16, and secondary outcomes are BMI, percent weight change, proportion of participants achieving 5% or more weight loss, dietary intake, physical activity, alcohol consumption, sleep, and stress across the study. A web-based wellness platform may be a scalable approach to promote behavioural changes that positively impact health. This study will inform the development and implementation of interventions using web-based wellness platforms and personalized digital interventions to improve health outcomes and reduce chronic disease risk among individuals with obesity.
Hemodialysis treatment aims to increase the life expectancy and quality of life of individuals. However, it is known that hemodialysis, which is a life-preserving treatment, causes many undesirable problems in physical, psychological, social and economic areas, in addition to its targeted effects. Muscle cramps and itching are two of the most common symptoms during the hemodialysis treatment process, and it is known that all problems and symptoms encountered during the treatment process negatively affect the quality of life and comfort level of individuals. Management of symptoms experienced by individuals receiving hemodialysis treatment is very important due to their effects on both quality of life and comfort level. It is known that the effects of pharmacological treatments are limited in the management of symptoms encountered during the treatment process. Therefore, there is an increasing trend towards non-pharmacological methods in the management of these symptoms. Music therapy is one of the important complementary treatments preferred by nurses and is a method used to manage symptoms and has no side effects. With music therapy, physical, psychological, emotional and social well-being is increased by utilizing the therapeutic aspect of music.
Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
OBJECTIVE: Osteoarthritis (OA) is a degenerative joint disease that affects elderly populations worldwide, causing pain and disability. Alteration of the fibroblast-like synoviocytes (FLSs) phenotype leads to an imbalance in the synovial inflammatory microenvironment, which accelerates the progression of OA. Despite this knowledge, the specific molecular mechanisms of the synovium that affect OA are still unclear.
METHODS: Both in vitro and in vivo experiments were undertaken to explore the role of ADAM8 playing in the synovial inflammatory of OA. A small interfering RNA (siRNA) was targeting ADAM8 to intervene. High-throughput sequencing was also used.
RESULTS: Our sequencing analysis revealed significant upregulation of the MAPK signaling cascade and ADAM8 gene expression in IL-1β-induced FLSs. The in vitro results demonstrated that ADAM8 blockade inhibited the invasion and migration of IL-1β-induced FLSs, while also suppressing the expression of related matrix metallomatrix proteinases (MMPs). Furthermore, our study revealed that inhibiting ADAM8 weakened the inflammatory protein secretion and MAPK signaling networks in FLSs. Mechanically, it revealed that inhibiting ADAM8 had a significant effect on the expression of migration-related signaling proteins, specifically FSCN1. When siADAM8 was combined with BDP-13176, a FSCN1 inhibitor, the migration and invasion of FLSs was further inhibited. These results suggest that FSCN1 is a crucial downstream factor of ADAM8 in regulating the biological phenotypes of FLSs. The in vivo experiments demonstrated that ADAM8 inhibition effectively reduced synoviocytes inflammation and alleviated the progression of OA in rats.
CONCLUSIONS: ADAM8 could be a promising therapeutic target for treating OA by targeting synovial inflammation.
BACKGROUND: Recent research has focused on the relationship between heart failure (HF) symptom clusters and outcomes, including mortality, hospitalization, functional status, and quality of life. No known studies to date have explored the role of physical HF symptom clusters and delays in seeking treatment.
OBJECTIVES: Describe physical symptom clusters in a population of HF patients and determine if a specific cluster is predictive of delay in seeking treatment for HF symptoms.
METHOD: We analyzed combined data from two studies ( n = 406) collected during acute HF hospitalization. The Heart Failure Somatic Awareness Scale quantified physical HF symptoms. Delay, measured in days, was collected from the medical record and confirmed by interview. Hierarchical agglomerative clustering techniques determined physical HF symptom clusters. Hierarchical multiple regression analysis was computed to explore predictors of delay.
RESULTS: Participants were primarily White, male sex older adults. Three physical HF symptom clusters were identified: discordant, edema-related, and dyspnea-related symptoms. Hierarchical multiple regression analysis revealed in Step 1 that age was a significant predictor of delay.
DISCUSSION: Our findings provide valuable insight into the role of physical symptom clusters on delay in persons with HF. Through agglomerative hierarchical clustering techniques, we found three physical HF symptom clusters that were then used to determine differences in cluster membership by demographic and clinical variables. Significant age differences were noted by cluster membership with youngest older adults in a discordant symptom cluster.
PURPOSE: A therapeutic agent containing purple bamboo salt prepared using bay salts and bamboo is provided to prevent or treat gastrorrhagia, inflammation, ulcer, and gastric mucosal injury. CONSTITUTION: A therapeutic agent for treating gastritis and gastric ulcer contains purple bamboo salts as an active ingredient, containing hydrogen sulfide. A method or preparing the purple bamboo salts comprises: a step of inputting bay salts and cut bamboo chips into a ceramic tank; a step of heating the ceramic tank at 1,000-1,200 Deg. C. for 50-90 minutes; a step of sealing and cooling the ceramic tank by 15-25 Deg. C.; a step of pulverizing the salts; and a step of repeating the steps 2-5 times. [Reference numerals] (AA) Hydrogen sulfide generation amount(μM, sample 10 g/L); (BB) Purified salt; (CC) Bay salts; (DD) Baked salts; (EE) Bamboo salts; (FF) Heat-treated purple salts
Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
1383085 Microspherical carbon particles; active carbon KUREHA KAGAKU KOGYO KK 28 March 1972 [27 Aug 1971] 14559/72 Heading C1A [Also in Division C5] Microspherical carbon particles of a diameter of from 10 to 5000 microns are produced by fusing a pitch having a softening point of 50‹ to 350‹ C.; a carbon content of 80 to 97% by weight and a hydrogen/carbon atomic ratio of 0À2 o 2À5 and a nitrobenzene insoluble fraction of 0 to 50% by weight, dispersing the fused pitch in an aqueous medium which contains a dispersing aid and has a temp. of 50-300‹ C.; cooling the dispersion to produce solid microspherical particles; separating and subjecting these particles to an infusibilization treatment in an oxidizing environment to raise their softening point and carbonizing these particles whilst still maintaining their particulate form. A solvent may be mixed with the pitch prior to dispersion, and this solvent is removed before the particles are treated to raise their softening point. The dispersing or suspending aid may be a water-soluble organic polymeric material e.g. partially saponified polyvinyl acetate, polyvinyl alcohol, methyl cellulose, polyacrylic acid, or salt thereof, polyethylene glycol or an ether or ester derivative thereof, starch, gelatin or mixtures thereof. The dispersing or suspension aid may be present in a concentration of from 0À05 to 5% by weight. The solvent for the pitch may be an aliphatic hydrocarbon, an aromatic hydrocarbon, or an alicyclic hydrocarbon. The softening point of the particles may be raised by contacting with an oxidizing liquid, e.g. H 2 SO 4 , H 3 PO 4 , HNO 3 , aqueous chromic acid or aqueous KMnO 4 . Alternatively, the oxidizing step may be performed in a gaseous oxidizing atmosphere, e.g. comprising MO 21 O 2 , O 3 , SO 2 , Cl 2 , Br 2  or mixtures thereof, or mixtures thereof with air M 2 , Ar, or other inert diluent gas. After carbonizing, the particles may be activated by contacting with steam at 800- 1200‹ C. The carbonization and activation may be performed sequentially in the same apparatus. The carbonization may be performed at a temp. sufficient to graphitize the particles, e.g. a temp. of 2800‹ to 3000‹ C.
INTRODUCTION: Suicidal hanging resulting in decapitation is rarely documented. This discussion involves a case of a 35-year-old man found decapitated in his residence's garden. A systematic literature review on hanging-induced decapitation was conducted to comprehensively investigate and compare the case to existing literature. The study aims to identify frequently described post-mortem findings in cases of suicidal hanging leading to decapitation.
CASE REPORT: A 35-year-old man was found decapitated in his garden, with a jute strap and chimney debris nearby. The cervical region was completely severed along the dorsoventral and craniocaudal plane, exposing internal structures. A ligature mark was present, along with Amussat's sign and Simon's bleeding.
METHODS: The systematic review of the literature followed PRISMA standards, analyzing 3622 publications from Google Scholar, PubMed, and Scopus databases up to 2023. Inclusion criteria comprised cases of complete or incomplete decapitation resulting from hanging, available in full-text and written in English.
RESULTS: 16 articles on hanging-induced decapitation met the selection criteria; 22 cases were analyzed. Studies, mostly from Europe, showed a mean victim age of 44.3, all male. Fall height ranged from 1 m to 18 m, with various suspension media. Most cases displayed complete decapitation, primarily between cervical vertebrae C1 and C3. Some cases noted collateral findings.
CONCLUSIONS: Complete crime scene investigation and thorough post-mortem examination are crucial for reconstructing events, especially with confounding elements. Precise evidence collection and literature comparison are essential to understand the case and substantiate the forensic pathologist's hypothesis in court.